 "Merck falls 14% in two days after CCI nod for acquisition by P&G")
Shares of Merck were locked in the lower circuit for the second straight day, down 5% at Rs 3,064 per share on the BSE, after the Competition Commission of India (CCI) approved the acquisition of 51.8% stake in the company by Procter and Gamble Overseas.
The stock has fallen 14% from its all-time high of Rs 3,549 recorded on Tuesday, September 3, 2018, on the BSE in intra-day trade. Till 11:49 am; a combined 42,423 equity shares changed hands and there were pending sell orders for 9,417 shares on the NSE and BSE.
“The Competition Commission of India has approved the proposed acquisition by Procter & Gamble Overseas India BV of 51.8% equity share capital of the company," Merck said in a press release to the exchanges on Tuesday.
"An approval has also been granted for the proposed transfer of the non-consumer health business of the company to Merck Life Science or any of its affiliates on a going concern basis by way of slump sale," the drug company added.
Since April 19, 2018, the stock of Merck zoomed 133% from Rs 1,510 after the Procter & Gamble Overseas India made a mandatory open offer to acquire 26% stake in the company at price of Rs 1,500.36 per share.
The stock has fallen 14% from its all-time high of Rs 3,549 recorded on Tuesday, September 3, 2018, on the BSE in intra-day trade. Till 11:49 am; a combined 42,423 equity shares changed hands and there were pending sell orders for 9,417 shares on the NSE and BSE.
“The Competition Commission of India has approved the proposed acquisition by Procter & Gamble Overseas India BV of 51.8% equity share capital of the company," Merck said in a press release to the exchanges on Tuesday.
"An approval has also been granted for the proposed transfer of the non-consumer health business of the company to Merck Life Science or any of its affiliates on a going concern basis by way of slump sale," the drug company added.
Since April 19, 2018, the stock of Merck zoomed 133% from Rs 1,510 after the Procter & Gamble Overseas India made a mandatory open offer to acquire 26% stake in the company at price of Rs 1,500.36 per share.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%